ClinicalTrials.gg
RecruitingNCT07704840STIPSUpdated Oct 1, 2026

A Pilot Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants With Post-Stroke Spasticity (The STIPS Study)

A Phase 2 interventional study of Administration of BMS-986368 and Placebo in Post-Stroke Spasticity, sponsored by Alberto Esquenazi. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Alberto Esquenazi · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 1, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,995 studies in Stroke with a site in United States — 392 open to participants now, 490 under way, 17 of them phase 3. Stroke · United States.

Planned enrollment
774th of 1,621
42 · median 40
Started
2026
with 104 others
Phase 2
163 of 1,995
21 open now
Primary completion
2027-06
later than 233 of 488 live
Registered
1,961st of 1,995
by date

Among the 1,995 studies in Stroke with a site in United States, this one is the 774th largest by planned enrollment of the 1,621 interventional ones that give a count, is one of 105 that started in 2026, is one of 163 in phase 2, reaches primary completion later than 233 of the 488 other live ones, and was the 1,961st registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

392 of the 1,995 studies in Stroke with a site in United States are open now. Recruiting first, the newest first:

386 more — sign in →

All 392 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,995 studies in Stroke with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the drug BMS-986368 works to treat post stroke spasticity in adults who have had a stroke. BMS-986368 is a designed to increase natural compounds in the body that may help calm nerves that cause muscles to be tight or spasm. The study will also learn about the safety of drug BMS-986368

Read the detailed description

Post-stroke spasticity (PSS) is a common and disabling complication of stroke that can impair upper-limb function, limit activities of daily living, and negatively affect quality of life. Current treatment options, including oral antispasticity medications and botulinum toxin injections, may provide incomplete symptom control and are often associated with tolerability limitations. Therefore, there is a need for novel therapies that can improve both spasticity and functional recovery in individuals with PSS. Preclinical evidence and early clinical experience support evaluation of BMS-986368 as a treatment for post-stroke spasticity. The STIPS Study is a Phase 2, randomized, double-blind, placebo-controlled pilot trial designed to evaluate the efficacy, safety, and tolerability of BMS-986368 in adults with post-stroke spasticity. The study consists of:

  • A screening period of up to 4 weeks
  • An 8-week double-blind treatment period
  • An optional 8-week double-blind active treatment extension (DBATE)
  • A 4-week safety follow-up period The maximum study duration is approximately 24 weeks. During the double-blind treatment period, participants randomized to active treatment will receive oral BMS-986368 with dose escalation from 1 mg once daily, to 3 mg once daily and then 6 mg once daily. Participants randomized to placebo will receive matching placebo capsules. Participants who complete the double-blind treatment period may elect to enter the DBATE, during which all participants receive active treatment while maintaining study blinding. The study hypothesis is that BMS-986368 administered up to 6 mg once daily will result in greater improvement in spasticity and upper-extremity motor function compared with placebo, while demonstrating an acceptable safety and tolerability profile in participants with post-stroke spasticity
03

Conditions studied

  • Post-Stroke Spasticity

Keywords

  • Stroke
  • Spasticity
  • Neurological Disorders
  • Upper Limb Spasticity
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ischemic or hemorrhagic stroke diagnosis 4 to 18 months prior to enrollment.
  • History of post stroke spasticity for at least 2 months prior to Screening Visit.
  • Modified Ashworth Scale (mAS) score ≥2 and \<4 for affected elbow and wrist joints at Screen and Baseline Visits.
  • Fugl-Meyer Assessment for Upper Extremity (FMA-UE) greater than 22 at Screen and Baseline Visits
  • Willing to participate with no therapy additions during study duration.
  • Participant must be able to read, speak, and understand English usage

Exclusion criteria

Exclusion Criteria:

Individuals who are pregnant or breastfeeding.

  • Participants must not have any concomitant disease or disorder that has symptoms of spasticity or that may influence the participant's level of spasticity.
  • Participants must not have a history of any substance abuse disorder as defined in , Fifth Edition (DSM-5) Diagnostic Criteria for Drug and Alcohol Abuse.
  • Participants must not be currently taking a medication for spasticity that cannot be discontinued and washed out prior to randomization.
  • Participants must not have used FAAH/MAGL inhibitor medication or any cannabinoid-related products (including cannabis, cannabidiol (CBD), or tetrahydrocannabinol (THC)) within 30 days prior to randomization.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Administration of BMS-986368

    Drug: BMS-986368. Specified dose on specified days

    Drug: Administration of BMS-986368

  • Placebo comparator
    Placebo

    Drug: Placebo Specified dose on specified days

    Drug: Placebo

Interventions

  • DrugAdministration of BMS-986368

    Administration of BMS-986368. Specified dose on specified days

  • DrugPlacebo

    Interventions: Drug: Placebo

06

What researchers measure

Primary outcomes

  1. Tardieu Scale

    Change from baseline in elbow and wrist Tardieu Scale. Clinical assessment with higher scores indicating greater spasticity.

    Time frame: At Week 8

  2. Upper Limb Fugl-Meyer Assessment (FMA-UE) Scale

    Change from baseline, Clinical Assessment of upper-extremity motor function and sensorimotor recovery after stroke. Scores range from 0 to 66, with higher scores indicating better motor function.

    Time frame: At Week 8

Secondary outcomes

  1. Tardieu Scale - DBATE

    Change from baseline in in elbow and wrist Tardieu Scale for participants in the Optional Active Treatment Extension Phase (DBATE).

    Time frame: At week 16

  2. Upper Limb Fugl-Meyer Assessment (FMA-UE) Scale- DBATE

    Change from baseline iat Week 16 for patients in the for patients in the Optional Active Treatment Extension Phase (DBATE)

    Time frame: At week 16

  3. Total Numeric-transformed Modified Ashworth Scale (TNmAS)

    Change from baseline in Total Numeric-transformed Modified Ashworth Scale; Clinician-rated measure of muscle tone/spasticity.

    Time frame: At week 8 for all participants. Additionally at Week 16 for participants in the Optional Active Treatment Extension phase

  4. Numeric Rating Scale - Spasticity (NRS-S)

    Change from baseline. Participant-rated severity of spasticity on a 0-10 scale

    Time frame: At Week 8 for all participants. At Week 16 for participants in the Optional Active Treatment Extension Phase

  5. Patient Health Questionnaire-9 (PHQ-9)

    Change from baseline in PHQ-9 Depression Scale. .The PHQ-9 participant-reported questionnaire used to assess the severity of depressive symptoms/

    Time frame: At Week 8 for all participants Additionally at Week 16 for participants in the Optional Active Treatment Extension Phase

  6. Clinical Global Impression of Severity (CGI-S)

    Change from baseline on the Clinical Global Impression of Severity (CGI-S) score. Clinician assessment of overall severity of spasticity-related impairment.

    Time frame: At Week 8 for all participants. Additionally at Week 16 for participants in the Optional Active Treatment Extension Phase

  7. Treatment-Emergent Adverse Events (TEAEs)

    Number of participants with Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to week 16]

  8. Serious adverse events (SAEs)

    Serious adverse events (SAEs)

    Time frame: Up to week 16

  9. Adverse events (AEs) leading to treatment discontinuation

    Adverse events (AEs) leading to treatment discontinuation

    Time frame: Up to week 16]

  10. AEs leading to death

    AEs leading to death

    Time frame: Up to week 16]

  11. AEs leading to clinically significant lab abnormalities

    AEs leading to clinically significant lab abnormalities

    Time frame: [Time Frame: Up to week 16]

  12. Suicidal Ideation and Behavior

    Number of participants with suicidal ideation and behavior during trial as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS).

    Time frame: Up to week 16]

  13. Cannabis Withdrawal Symptoms

    Number of participants with withdrawal symptoms following BMS-986368 administration as assessed by the Cannabis Withdrawal Scale (CWS).

    Time frame: Up to week 24

  14. Plasma concentrations of BMS-986368

    Plasma concentrations of BMS-986368 at selected pre- and post-dose time points

    Time frame: Up to Week 8

07

Study locations

1 of 1 sites recruiting
  • Jeffersi=on Moss Magee Rehabilitation
    Elkins Park, Pennsylvania 19027, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Our intention is to provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. However, we are answering this item as "undecided" while specific details are determined.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.

Of 112 non-industry phase 2 interventional studies under Stroke, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 9 months is below that.

Counting every sponsor, half of 132 studies reached it within 40 months; a quarter within 24 and three quarters within 59.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Jul 15, 2026
StartActual
Sep 2, 2026was Jul 2026
Primary completionEst.
Jun 2027
CompletionEst.
Aug 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 2026→Sep 2, 2026 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Start date Jul 2026→Sep 2, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07704840
Lead sponsor
Alberto Esquenazi
Responsible party
Alberto Esquenazi (Chief Clinical Officer Jefferson Moss-Magee Rehabilitation, Thomas Jefferson University) — Sponsor-investigator
First posted
Jul 15, 2026
Start date
Sep 2, 2026
Primary completion
Jun 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Kareema Murray
Contact
kareema.murray@jefferson.edu
215-663-6290
Alberto Esquenazi, MD
study director · Thomas Jefferson University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion